Literature DB >> 15703863

Can peripheral DXA measurements be used to predict fractures in elderly women living in the community?

R J Barr1, A Adebajo, W D Fraser, J P Halsey, C Kelsey, A Stewart, D M Reid.   

Abstract

While axial dual energy X-ray absorptiometry (DXA) is the accepted "gold standard" method both for diagnosing osteoporosis and predicting fractures, appropriate equipment is not universally available. Peripheral bone mass measurements may have the potential to identify patients at risk of fracture and to be used to target appropriate treatment. We assessed the effectiveness of peripheral DXA (PIXI, GELunar) in the assessment of risk and targeting treatment to prevent future fracture in 7,604 women aged 60-80 from five centres across Britain. At enrolment women completed a lifestyle and risk factor questionnaire and had a PIXI DXA scan of the heel. Women were categorised by PIXI DXA bone mineral density (BMD) into high, medium or low risk of future osteoporotic fracture. Treatment was recommended to those at highest risk. Follow-up was by simple questionnaire 18-24 months after baseline assessment. Seventy-four percent returned the follow-up questionnaire. The area under the receiver operator characteristic (ROC) curves for any fracture and osteoporotic fracture were comparable to those published using other sites and technologies. A 1-SD decrease in PIXI BMD was associated with an 86% increase in risk of osteoporotic fracture. Of the women identified as high risk, 74% had started treatment following their heel scan and 84.7% continued to take treatment at follow-up. No significant difference was noted in fracture rates in those who started treatment after assessment compared to those who did not. While peripheral DXA is highly effective for predicting older women who are at increased risk of future fracture, it has yet to be established as an effective method for targeting bisphosphonate or other therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703863     DOI: 10.1007/s00198-005-1836-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  13 in total

1.  Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment.

Authors:  Paul D Miller; Ethel S Siris; Elizabeth Barrett-Connor; Kenneth G Faulkner; Lois E Wehren; Thomas A Abbott; Ya-Ting Chen; Marc L Berger; Arthur C Santora; Louis M Sherwood
Journal:  J Bone Miner Res       Date:  2002-12       Impact factor: 6.741

2.  Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS Study Group. European Prospective Osteoporosis Study Group.

Authors:  A A Ismail; T W O'Neill; W Cockerill; J D Finn; J B Cannata; K Hoszowski; O Johnell; C Matthis; H Raspe; A Raspe; J Reeve; A J Silman
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

3.  Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease.

Authors:  J A Kanis; P Delmas; P Burckhardt; C Cooper; D Torgerson
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

4.  Identification of women with reduced bone density at the lumbar spine and femoral neck using BMD at the os calcis.

Authors:  J N Fordham; D J Chinn; N Kumar
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

5.  Use of a peripheral dexa measurement for osteoporosis screening.

Authors:  Julienne K Kirk; Mindy Nichols; John G Spangler
Journal:  Fam Med       Date:  2002-03       Impact factor: 1.756

6.  A prospective study on socioeconomic aspects of fracture of the proximal femur.

Authors:  M A Schürch; R Rizzoli; B Mermillod; H Vasey; J P Michel; J P Bonjour
Journal:  J Bone Miner Res       Date:  1996-12       Impact factor: 6.741

Review 7.  Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population.

Authors:  P D Miller; S L Bonnick; C J Rosen
Journal:  Calcif Tissue Int       Date:  1996-04       Impact factor: 4.333

8.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

Review 9.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

10.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

Authors:  D Marshall; O Johnell; H Wedel
Journal:  BMJ       Date:  1996-05-18
View more
  5 in total

Review 1.  The role of DXA bone density scans in the diagnosis and treatment of osteoporosis.

Authors:  Glen M Blake; Ignac Fogelman
Journal:  Postgrad Med J       Date:  2007-08       Impact factor: 2.401

2.  Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound.

Authors:  A Díez-Pérez; J González-Macías; F Marín; M Abizanda; R Alvarez; A Gimeno; E Pegenaute; J Vila
Journal:  Osteoporos Int       Date:  2007-01-18       Impact factor: 4.507

3.  Association of Methylene Tetrahydrofolate Reductase Polymorphism with BMD and Homocysteine in Premenopausal North Indian Women.

Authors:  Sanjeev Kumar Pandey; Ankur Singh; Sunil Kumar Polipalli; Sangeeta Gupta; Seema Kapoor
Journal:  J Clin Diagn Res       Date:  2013-12-15

4.  Self-reported frailty is associated with low calcaneal bone mineral density in a multiracial population of community-dwelling elderly.

Authors:  S-L Ma; J Oyler; S Glavin; A Alavi; T Vokes
Journal:  Osteoporos Int       Date:  2009-03-18       Impact factor: 4.507

5.  Utility of heel dual-energy X-ray absorptiometry in diagnosing osteoporosis.

Authors:  Sharon H Chou; Jessica Hwang; Siu-Ling Ma; Tamara Vokes
Journal:  J Clin Densitom       Date:  2013-10-19       Impact factor: 2.617

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.